OncRef
Skip to newsletter content
|
RCCJune 2026
0:00 / 3:28
Renal Cell Carcinoma — Monthly Compass
Jun 01–30, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in renal cell carcinoma this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
renal cell carcinoma updates
Key Highlights
Key Highlights
  • Practice-Changing Updates
    • On June 12, 2026, the FDA approved belzutifan (Welireg) with pembrolizumab—or with pembrolizumab and berahyaluronidase alfa‑pmph (Keytruda Qlex)—as adjuvant therapy for adults with ccRCC at intermediate‑high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions, based on a prespecified interim LITESPARK‑022 analysis showing disease‑free survival improvement, with labeling that includes a boxed warning for embryo‑fetal toxicity and warnings for anemia and hypoxia.
  • Key Clinical Development Updates
    • Merck disclosed RCC regulatory timelines indicating a June 19, 2026 PDUFA target for adjuvant Welireg + Keytruda and an October 4, 2026 PDUFA date for Welireg + lenvatinib in post‑IO advanced RCC (LITESPARK‑011), defining near‑term U.S. review milestones across perioperative and refractory settings.
    • The adjuvant belzutifan + pembrolizumab application received Priority Review and was reviewed under Project Orbis using the FDA Assessment Aid, documenting expedited, collaborative regulatory assessment for high‑risk ccRCC.
  • Important Clinical Trial Publications
    • June 2026 Journal of Clinical Oncology meeting abstracts reported ctDNA analyses from KEYNOTE‑564 supporting MRD‑informed adjuvant risk stratification and described multi‑axis circulating protein models (KIM‑1/MAdCAM‑1) plus spatial transcriptomics associated with sunitinib response, enabling biologically guided selection of IO/TKI strategies in metastatic RCC.
  • Key Conference Updates
    • At ASCO 2026 (May 29–June 2), RCC presentations featured the phase 3 PEAK‑1 trial of casdatifan + cabozantinib after anti‑PD‑(L)1, a June 3 collaboration adding the PD‑L1/VEGF‑A bispecific pumitamig to casdatifan regimens, the phase 3 LUTEON trial of 177Lu‑girentuximab with mandatory 89Zr‑girentuximab PET selection, and perioperative/neoadjuvant studies of zanzalintinib ± nivolumab for surgically challenging or bone‑metastatic disease.
    • Anticipated near‑term milestones include interim PEAK‑1 progression‑free survival and quality‑of‑life analyses and LUTEON enrollment progress.
  • Emerging Themes & Macro-Trends
    • HIF‑2α–anchored combinations, including HIF‑2α + VEGFR‑TKI doublets and potential triplets with a PD‑L1/VEGF‑A bispecific, are positioned to reshape post‑IO sequencing while CAIX‑PET–selected radioligand therapy emerges as a biomarker‑defined line of therapy requiring investment in PET access and center capabilities.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • On June 12, 2026, the FDA approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. Efficacy was evaluated in LITESPARK-022 (NCT05239728), a multicenter, double-blind, randomized trial in 1,841 patients with prior nephrectomy for ccRCC. A statistically significant improvement in disease-free survival (DFS) was demonstrated at a prespecified interim analysis. The belzutifan prescribing information includes a boxed warning for embryo-fetal toxicity and warnings and precautions for anemia and hypoxia.¹ (read more)
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • FDA approved Merck’s belzutifan (Welireg) in combination with pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa‑pmph (Keytruda Qlex) on June 12, 2026 for adjuvant treatment of adults with ccRCC at intermediate‑high or high risk of recurrence post‑nephrectomy; the submission received Priority Review and was reviewed under Project Orbis using the FDA’s Assessment Aid tool. The announcement cites efficacy from LITESPARK‑022 and specifies boxed and safety warnings for belzutifan, meeting the regulatory milestone criteria. ¹ (fda.gov) (read more)
  • Merck’s ASCO 2026 Investor Event deck (published June 1, 2026; updated June 9, 2026) highlighted two RCC regulatory timelines: a June 19, 2026 PDUFA target action date for adjuvant Welireg + Keytruda based on LITESPARK‑022, and an October 4, 2026 PDUFA date for Welireg + lenvatinib in post‑IO advanced RCC (LITESPARK‑011). These disclosures constitute corporate regulatory updates identifying active FDA reviews and specific PDUFA milestones. ² (s21.q4cdn.com) (read more)
Conference
Major Conference Updates
Conference Information
  • 2026 ASCO Annual Meeting, McCormick Place, Chicago, IL; May 29–June 2, 2026. Overall, RCC content in June 2026 signaled a pivot toward HIF-2α–based intensification across perioperative and post–IO settings, rapid maturation of CAIX-targeted radiotherapeutics, and a clear push to embed biomarkers/MRD to personalize therapy. (read more)
  • Theme 1: HIF‑2α Intensification and Post‑IO Combinations
    • Significance: HIF‑2α blockade moved center stage, with adjuvant uptake accelerated by FDA action and post‑immunotherapy combinations advancing to phase 3—positioning HIF‑2α as the anchor for next‑line strategy. (read more)
    • Mechanism insights / clinical impact: Targeting VHL‑HIF signaling (belzutifan, casdatifan) complements anti‑VEGFR TKIs; PEAK‑1 (casdatifan + cabozantinib) is designed to improve PFS after anti–PD‑(L)1, while a June 3 collaboration adds a PD‑L1/VEGF‑A bispecific (pumitamig) to test tripartite pathway control. (read more)
    • Patient populations affected: High‑risk ccRCC in the adjuvant setting (belzutifan + pembrolizumab); advanced ccRCC progressing after anti‑PD‑(L)1 (PEAK‑1). (read more)
  • Theme 2: CAIX‑Targeted Radiotherapeutics Enter Late‑Stage Testing
    • Significance: Radiotheranostics advanced with LUTEON, a phase 3 study of 177Lu‑girentuximab, signaling potential for image‑selected, organ‑sparing disease control and quality‑of‑life preservation. (read more)
    • Mechanism insights / clinical impact: CAIX‑directed mAb therapy delivers 177Lu to ccRCC; mandatory 89Zr‑girentuximab PET enriches for CAIX‑positive tumors—an operational blueprint for precision radioligand therapy in RCC. (read more)
    • Patient populations affected: Advanced, relapsed, or recurrent ccRCC with CAIX‑positive disease by PET. (read more)
  • Theme 3: Biomarker‑Guided Personalization (ctDNA, Circulating Proteins, Spatial TME)
    • Significance: June ASCO abstracts emphasized MRD/biomarker integration to refine adjuvant and metastatic decisions—key to optimizing benefit and avoiding overtreatment. (read more)
    • Mechanism insights / clinical impact: ctDNA analyses from KEYNOTE‑564 support MRD‑informed adjuvant risk stratification; circulating KIM‑1/MAdCAM‑1 multi‑axis models and spatial transcriptomics linked to sunitinib response enable biology‑based tailoring of IO/TKI. (read more)
    • Patient populations affected: Resected ccRCC receiving adjuvant therapy; 1L IO‑treated mccRCC; patients considered for VEGFR‑TKI where TME features influence benefit. (read more)
  • Theme 4: Perioperative IO/TKI to Enable Surgery and Address Special‑Risk Cohorts
    • Significance: Movement into neoadjuvant/perioperative care aims to downstage surgically challenging tumors and address under‑served groups (eg, bone metastases). (read more)
    • Mechanism insights / clinical impact: Zanzalintinib (next‑gen VEGFR/MET/AXL TKI) plus nivolumab (EXPLORE‑RCC) tests cytoreduction pre‑op; ZAMBONI evaluates single‑agent zanzalintinib with endpoints tailored to skeletal disease burden and SREs. PROSPER analyses inform future neoadjuvant trial design. (read more)
    • Patient populations affected: Locally advanced/surgically challenging ccRCC candidates for nephron‑sparing or margin‑negative resections; mccRCC with bone metastases post‑ICI. (read more)
  • Significance
    • Expected clinical or translational readouts: Interim PEAK‑1 (PFS, QoL) and LUTEON enrollment milestones; maturation of MRD/biomarker datasets to guide adjuvant selection. (ascopubs.org) (read more)
    • Regulatory or policy implications: June 12 approval of belzutifan + pembrolizumab establishes a new adjuvant benchmark and raises bar for future perioperative regimens. (read more)
    • Potential shifts in standard of care: HIF‑2α–anchored combinations likely to reshape post‑IO sequencing; CAIX‑PET–selected radioligand therapy could open a novel line‑of‑therapy for biomarker‑positive ccRCC. (ascopubs.org) (read more)
    • Strategic implications: Invest in HIF‑2α + VEGFR‑TKI (and bispecific) triplets; secure CAIX‑PET access and center capabilities; accelerate MRD‑driven perioperative trials to defend adjuvant share. (read more)
Publications Related to Approved Drugs
Unknown Drug
There are no new publication updates during the 2026-06-01 to 2026-06-30 for renal cell carcinoma.
New Publications Related to Drugs in Clinical Trial Development
Phase 2
Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study. A study on patient preference for pembrolizumab administration found that a subcutaneous (SC) formulation was preferred over the intravenous (IV) route by 65% of participants, mainly due to reduced clinic time. The SC option demonstrated comparable safety and greater convenience, suggesting it as a favorable alternative for cancer treatment. ()
Phase 2
Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors. This study demonstrates that an AI-powered analysis of the tumor microenvironment can predict patient outcomes to pembrolizumab in rare tumors. An on-treatment increase in tumor-infiltrating lymphocytes combined with a decrease in tumor content was significantly associated with improved progression-free and overall survival, highlighting a potential biomarker strategy. ()
Phase 3
Discovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2α. The discovery of casdatifan, a potent and orally bioavailable HIF-2α inhibitor, presents a promising new therapeutic for clear cell renal cell carcinoma (ccRCC). With a pharmacokinetic profile suitable for once-daily dosing, it is now advancing to a Phase 3 trial in combination with cabozantinib for patients with advanced disease. ()
Phase 1
Intravenous Everolimus Formulation (Sapu003) for Clinical Trials. A novel intravenous (IV) formulation of everolimus, Sapu003, has been developed to overcome the drug's poor oral bioavailability, showing potent antitumor efficacy in preclinical models. This formulation's scalable manufacturing and stability have enabled its progression into a Phase 1b clinical trial for patients with advanced mTOR-sensitive solid tumors. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in renal cell carcinoma updated from 2026-06-01 to 2026-06-30:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation-------
Not Yet Recruiting-11---2
Recruiting416-1113
Available-------
Approved for Marketing-------
Active, Not Recruiting423-1-10
Completed-------
Total8410-2125
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Leucovorin, Gemcitabine, Irinotecan, Paclitaxel, Pembrolizumab, Bevacizumab, Nivolumab, Ramucirumab, Imiquimod Cream, PLD, 5-FU, Cisplatin, Carboplatin, : TRK-950 NCT03872947 ACTIVE_NOT_RECRUITING A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors 2026-06
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
No phase 2 trials completing within the next three months.
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Avelumab NCT03815643 ACTIVE_NOT_RECRUITING An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies 2026-08-21
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.